The Hottest Topic In Soft Tissue - Double-Bundle ACL Published recently in The Journal of Bone and Joint Surgery - British Volume (JBJS-Br) is an annotation discussing the evidence for and against double-bundle arthroscopic reconstruction of the anterior cruciate ligament which will no doubt court controversy.
Source: www.medicalnewstoday.comProstatitis And Inflammatory Conditions Of The Prostate Objectives * Provide an overview of the prostatitis syndromes * Present a practical approach to diagnosis * Summarize current treatment options Materials and Methods The recent literature on the prostatitis syndromes was reviewed with particular reference to randomized controlled clinical trials (RCTs).
Source: www.medicalnewstoday.comIn Preparation For The Next Influenza ('flu) Season, The U.S. FDA Has Approved Six Vaccines For 2008-09 With the approval, the U.S. FDA has targeted three new strains of 'flu. Six pharma firms will benefit from the approval, including GlaxoSmithKline, MedImmune (part of AstraZeneca), and Sanofi Pasteur.
Source: www.medicalnewstoday.comEdinburgh Clinical Dental Technician Course A UK First The first stand-alone course for clinical dental technicians in the UK will begin in Edinburgh later this year following provisional approval from the General Dental Council. The course is open to GDC-registered dental technicians. The GDC gave provisional approval to the 37-week course at the Edinburgh Dental Institute at a recent meeting.
Source: www.medicalnewstoday.comMinimally Invasive Surgical Therapy And Lower Urinary Tract Symptoms Treatment Evidence Based Treatment UroToday.com - The new paradigm in the treatment of Lower Urinary Tract Symptoms (LUTS) is towards both medical management and minimally invasive surgery. LUTS is a symptom complex that includes both irritative as well as obstructive symptoms. Generally, surgical treatment is directed at the obstructive component.
Source: www.medicalnewstoday.comPhase 3 Trial With Investigational Hepatitis B Vaccine (HEPLISAV) Met Primary Endpoint Dynavax Technologies Corporation (Nasdaq:DVAX) and Merck & Co., Inc. announced today top-line immunogenicity results from a Phase 3 clinical trial comparing HEPLISAV™, an investigational hepatitis B virus (HBV) vaccine, to a currently marketed HBV vaccine, Engerix-B® (1). The study achieved its primary endpoint.
Source: www.medicalnewstoday.comInternational Health Challenge Seeks Participants For Obesity Prevention Research The University of Houston department of
health and human performance is launching an international effort to recruit 500 participants for a study promoting
healthy dietary habits and physical activity. The study will take place entirely in the virtual world of Second Life (SL).
Source: www.medicalnewstoday.comNon-Muscle Invasive Transitional Cell Carcinoma UroToday.com - G1-3pTa/1 TCC accounts for up to 80% of all newly diagnosed bladder cancer. Whilst bladder cancer is the 5th commonest cancer it is the most expensive disease to manage because of its propensity to recur and progress. Identifying risk of recurrence and/or progression is essential in order to plan management.
Source: www.medicalnewstoday.com
# posted by Network @ 5:00 PM
